US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kalaris Therapeutics Inc.

2.70

-0.1500-5.26%

Post-market: 2.700.00000.00%16:10 EDT

Volume:235.76K

Turnover:634.00K

Market Cap:64.24M

PE:-1.31

High:2.90

Open:2.90

Low:2.51

Close:2.85

52wk High:11.88

52wk Low:2.51

Shares:23.79M

Float Shares:7.23M

Volume Ratio:3.32

T/O Rate:3.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0646

EPS(LYR):-2.8500

ROE:-79.91%

ROA:-31.03%

PB:1.11

PE(LYR):-0.95

Loading ...

Overview Company News Filings

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

Kalaris Therapeutics Inc Q1 Net Income USD -10.856 Million VS. Ibes Estimate USD -11.7 Million

THOMSON REUTERS

Kalaris Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Kalaris Therapeutics announces annual shareholder meeting

Kalaris Therapeutics Inc - May Sell Common Stock up to $100 Mln Through or to TD Cowen - SEC Filing

THOMSON REUTERS

BRIEF-Kalaris Therapeutics Inc - Matthew Gall Resigns As CFO Effective April 14, 2026 - SEC Filing

Kalaris Therapeutics Inc - Brett Hagen to Serve as Principal Financial Officer Effective April 14, 2026 - SEC Filing

THOMSON REUTERS

Kalaris CFO Matthew Gall resigns; Chief Accounting Officer Brett Hagen named principal financial officer

Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares

Kalaris Therapeutics FY 2025 net loss narrows 37% to USD 43.44 million

Press Release: Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/KLRS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":2.7,"timestamp":1790971200000,"preClose":2.85,"halted":0,"volume":235755,"hourTrading":{"tag":"盘后","latestPrice":2.7,"preClose":2.7,"latestTime":"16:10 EDT","volume":233,"amount":629.1,"timestamp":1790971804856,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05263157894736839,"floatShares":7230800,"shares":23792278,"eps":-2.064571,"marketStatus":"Post-Mkt","change":-0.15,"latestTime":"10-02 18:57:29 EDT","open":2.9,"high":2.9,"low":2.51,"amount":633999,"amplitude":0.136842,"askPrice":2.78,"askSize":1,"bidPrice":2.47,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-2.064571,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790985600000},"marketStatusCode":4,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":2.85,"preHourTrading":{"tag":"盘前","latestPrice":2.6681,"preClose":2.85,"latestTime":"05:56 EDT","volume":1,"amount":2.6681,"timestamp":1790934997856,"change":-0.1819,"changeRate":-0.063825,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.7,"preClose":2.7,"latestTime":"16:10 EDT","volume":233,"amount":629.1,"timestamp":1790971804856,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.32039},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":7230800,"roa":"-31.03%","roe":"-79.91%","lyrEps":-2.849999,"volumeRatio":3.32039,"shares":23792278,"dividePrice":0,"high":2.9,"amplitude":0.136842,"preClose":2.85,"low":2.51,"week52Low":2.51,"pbRate":"1.11","week52High":11.88,"institutionHeld":0,"latestPrice":2.7,"committee":0.6,"eps":-2.064571,"divideRate":0,"volume":235755,"delay":0,"ttmEps":-2.064571,"open":2.9,"prevYearClose":8.44,"prevWeekClose":2.92,"prevMonthClose":2.89,"prevQuarterClose":2.89,"fiveDayClose":2.92,"twentyDayClose":3.94,"sixtyDayClose":4.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"KLRS","fiscalQuarterEnding":"2026/06","expectedEps":-0.5,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2026-05-12","symbol":"KLRS","fiscalQuarterEnding":"2026/03","expectedEps":-0.52,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2026-03-17","symbol":"KLRS","fiscalQuarterEnding":"2025/12","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773720000000,"reportTimeType":"pre","actualEps":-0.44},{"market":"US","date":"2025-11-12","symbol":"KLRS","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.64},{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1781582400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2026-10-01","current":-1.307778,"percent":0.650919,"low":-3.702314,"twenty":-2.949422,"median":-2.106127,"eighty":-0.913935,"high":-0.558935,"avg":-1.971523,"sd":0.940548,"marketCap":68796395},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143},{"date":"2025-10-10","current":-1.059306,"twenty":-1.715927,"median":-0.815379,"eighty":-0.632803,"marketCap":86498683},{"date":"2025-10-17","current":-1.097097,"twenty":-1.652483,"median":-0.853303,"eighty":-0.634281,"marketCap":89584582},{"date":"2025-10-24","current":-1.120001,"twenty":-1.598641,"median":-0.878784,"eighty":-0.635266,"marketCap":91454824},{"date":"2025-10-31","current":-1.085645,"twenty":-1.578566,"median":-0.913935,"eighty":-0.635266,"marketCap":88649461},{"date":"2025-11-07","current":-1.083355,"twenty":-1.543053,"median":-0.93448,"eighty":-0.63822,"marketCap":88462437},{"date":"2025-11-14","current":-1.220778,"twenty":-1.513949,"median":-0.991739,"eighty":-0.641667,"marketCap":99683887},{"date":"2025-11-21","current":-2.326591,"twenty":-1.652483,"median":-1.007772,"eighty":-0.642652,"marketCap":129046684},{"date":"2025-11-28","current":-2.104047,"twenty":-1.7661,"median":-1.019224,"eighty":-0.643637,"marketCap":116703088},{"date":"2025-12-05","current":-1.996147,"twenty":-1.811647,"median":-1.04043,"eighty":-0.647085,"marketCap":110718314},{"date":"2025-12-12","current":-2.808768,"twenty":-1.83375,"median":-1.046709,"eighty":-0.650039,"marketCap":155791141},{"date":"2025-12-19","current":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"marketCap":194879195},{"date":"2025-12-26","current":-3.230252,"twenty":-1.885652,"median":-1.065031,"eighty":-0.655456,"marketCap":179169164},{"date":"2026-01-02","current":-2.845859,"twenty":-1.914397,"median":-1.075338,"eighty":-0.657426,"marketCap":157848407},{"date":"2026-01-09","current":-2.785165,"twenty":-1.996147,"median":-1.083355,"eighty":-0.657426,"marketCap":154481972},{"date":"2026-01-16","current":-2.987477,"twenty":-2.104047,"median":-1.089081,"eighty":-0.657426,"marketCap":165703423},{"date":"2026-01-23","current":-3.29769,"twenty":-2.164782,"median":-1.092517,"eighty":-0.659396,"marketCap":182909648},{"date":"2026-01-30","current":-3.102121,"twenty":-2.196152,"median":-1.097097,"eighty":-0.661858,"marketCap":172062245},{"date":"2026-02-06","current":-2.815512,"twenty":-2.367922,"median":-1.114275,"eighty":-0.662351,"marketCap":156165190},{"date":"2026-02-13","current":-3.02794,"twenty":-2.502772,"median":-1.122292,"eighty":-0.662351,"marketCap":167947713},{"date":"2026-02-20","current":-3.702314,"twenty":-2.785165,"median":-1.136034,"eighty":-0.665305,"marketCap":205352549},{"date":"2026-02-27","current":-3.560695,"twenty":-2.810117,"median":-1.145196,"eighty":-0.674662,"marketCap":197497534},{"date":"2026-03-06","current":-3.262285,"twenty":-2.841832,"median":-1.152067,"eighty":-0.679587,"marketCap":180945894},{"date":"2026-03-13","current":-3.092005,"twenty":-2.933528,"median":-1.165399,"eighty":-0.681064,"marketCap":171501173},{"date":"2026-03-20","current":-2.932075,"twenty":-2.973316,"median":-1.284909,"eighty":-0.685003,"marketCap":127363466},{"date":"2026-03-27","current":-3.072027,"twenty":-2.992198,"median":-1.357057,"eighty":-0.692882,"marketCap":133442723},{"date":"2026-04-02","current":-3.132729,"twenty":-3.014452,"median":-1.458617,"eighty":-0.697807,"marketCap":136079478},{"date":"2026-04-10","current":-3.203987,"twenty":-3.059472,"median":-1.52082,"eighty":-0.701747,"marketCap":139174799},{"date":"2026-04-17","current":-3.478464,"twenty":-3.075922,"median":-1.602849,"eighty":-0.708887,"marketCap":151097516},{"date":"2026-04-24","current":-3.219822,"twenty":-3.095853,"median":-1.746752,"eighty":-0.714058,"marketCap":139862648},{"date":"2026-05-01","current":-2.913675,"twenty":-3.10064,"median":-1.776394,"eighty":-0.714058,"marketCap":126564232},{"date":"2026-05-08","current":-2.725961,"twenty":-3.095853,"median":-1.811647,"eighty":-0.715043,"marketCap":118410298},{"date":"2026-05-15","current":-2.72166,"twenty":-3.087959,"median":-1.820952,"eighty":-0.717998,"marketCap":120019759},{"date":"2026-05-22","current":-2.669521,"twenty":-3.080541,"median":-1.83767,"eighty":-0.723661,"marketCap":117720529},{"date":"2026-05-29","current":-2.700804,"twenty":-3.078518,"median":-1.841041,"eighty":-0.729817,"marketCap":119100067},{"date":"2026-06-05","current":-2.429681,"twenty":-3.07722,"median":-1.863022,"eighty":-0.734741,"marketCap":107144076},{"date":"2026-06-12","current":-2.352359,"twenty":-3.072027,"median":-1.890061,"eighty":-0.741636,"marketCap":103734332},{"date":"2026-06-18","current":-2.45487,"twenty":-3.072027,"median":-1.911693,"eighty":-0.753455,"marketCap":108254864},{"date":"2026-06-26","current":-2.319987,"twenty":-3.071774,"median":-1.965772,"eighty":-0.758379,"marketCap":102306795},{"date":"2026-07-02","current":-2.44408,"twenty":-3.063682,"median":-1.990247,"eighty":-0.758379,"marketCap":107779019},{"date":"2026-07-10","current":-2.422498,"twenty":-3.057285,"median":-2.077072,"eighty":-0.760349,"marketCap":106827328},{"date":"2026-07-17","current":-2.487242,"twenty":-3.052473,"median":-2.104047,"eighty":-0.764781,"marketCap":109682401},{"date":"2026-07-24","current":-2.114965,"twenty":-3.046817,"median":-2.114965,"eighty":-0.793344,"marketCap":93265729},{"date":"2026-07-31","current":-1.877571,"twenty":-3.035018,"median":-2.104047,"eighty":-0.807625,"marketCap":82797127},{"date":"2026-08-07","current":-2.260639,"twenty":-3.007709,"median":-2.112878,"eighty":-0.814247,"marketCap":99689644},{"date":"2026-08-14","current":-2.08558,"twenty":-2.992198,"median":-2.117831,"eighty":-0.818113,"marketCap":92314038},{"date":"2026-08-21","current":-2.215768,"twenty":-2.988826,"median":-2.131838,"eighty":-0.837815,"marketCap":98076521},{"date":"2026-08-28","current":-2.205011,"twenty":-2.983431,"median":-2.16316,"eighty":-0.854016,"marketCap":97600422},{"date":"2026-09-04","current":-2.118962,"twenty":-2.978711,"median":-2.160644,"eighty":-0.865734,"marketCap":93791625},{"date":"2026-09-11","current":-1.774765,"twenty":-2.976168,"median":-2.131838,"eighty":-0.8745,"marketCap":78556437},{"date":"2026-09-18","current":-1.699472,"twenty":-2.972873,"median":-2.117831,"eighty":-0.883655,"marketCap":75223739},{"date":"2026-09-25","current":-1.65107,"twenty":-2.963874,"median":-2.112878,"eighty":-0.900151,"marketCap":73081291},{"date":"2026-10-01","current":-1.554264,"twenty":-2.949422,"median":-2.106127,"eighty":-0.913935,"marketCap":68796395}],"updateTime":1790981849034},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634164872","title":"Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634164872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634164872?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1C0RQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634161272","title":"Kalaris Therapeutics Inc Q1 Net Income USD -10.856 Million VS. Ibes Estimate USD -11.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634161272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634161272?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLX5B3435:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633046832","title":"Kalaris Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633046832","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633046832?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:30","pubTimestamp":1778254228,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630827688","title":"Kalaris Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630827688","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630827688?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:31","pubTimestamp":1777062662,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics will hold its 2026 annual meeting of stockholders online on June 3, 2026.Voting items include election of three Class III directors for terms expiring at 2029 annual meeting.Stockholders will also vote on a non-binding advisory resolution on executive compensation.Another advisory vote will set preferred frequency for future executive compensation votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDLbP2Qlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627465331","title":"Kalaris Therapeutics Inc - May Sell Common Stock up to $100 Mln Through or to TD Cowen - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627465331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627465331?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:21","pubTimestamp":1776111692,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0IN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626914881","title":"BRIEF-Kalaris Therapeutics Inc - Matthew Gall Resigns As CFO Effective April 14, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2626914881","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626914881?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:18","pubTimestamp":1775852301,"startTime":"0","endTime":"0","summary":"BRIEF-Kalaris Therapeutics Inc - Matthew Gall Resigns As CFO Effective April 14, 2026 - SEC FilingApril 10  - Kalaris Therapeutics Inc KLRS.O:KALARIS THERAPEUTICS INC - MATTHEW GALL RESIGNS AS CFO EFFECTIVE APRIL 14, 2026 - SEC FILINGSource text: []Further company coverage: KLRS.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T056:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148327","title":"Kalaris Therapeutics Inc - Brett Hagen to Serve as Principal Financial Officer Effective April 14, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148327","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148327?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:03","pubTimestamp":1775851399,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T056:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626431110","title":"Kalaris CFO Matthew Gall resigns; Chief Accounting Officer Brett Hagen named principal financial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626431110","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626431110?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:02","pubTimestamp":1775851372,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics CFO Matthew Gall resigned effective April 14, 2026.Hagen has served as chief accounting officer since January 2019.He previously held finance and accounting leadership roles at Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL3Jn1Pq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","KLRS","ELOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081475","title":"Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081475","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081475?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:06","pubTimestamp":1774296411,"startTime":"0","endTime":"0","summary":"Brett Hagen, Chief Accounting Officer at Kalaris Therapeutics, reported selling 1,915 shares of common stock at USD 6.72 on March 20, 2026.Following the transaction, Hagen reported directly owning 0 shares of common stock.Hagen reported receiving a stock option for 60,800 shares with an exercise price of USD 6.81 on March 19, 2026.After the grant, Hagen reported directly holding 60,800 stock options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information containe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL7gl18Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620210104","title":"Kalaris Therapeutics FY 2025 net loss narrows 37% to USD 43.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620210104","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620210104?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:04","pubTimestamp":1773749093,"startTime":"0","endTime":"0","summary":"Kalaris published a press release reporting full-year financial results and business updates. For FY 2025, net loss was USD 43.44 million, narrowing 37.2%, while research and development expenses fell 31.7% to USD 30.75 million, mainly due to a USD 32.0 million royalty obligation expense recorded in the prior year. General and administrative expenses rose more than doubled to USD 15.4 million, driven by higher insurance, legal, accounting and other professional fees and personnel costs related to operating as a public company. Cash, cash equivalents and marketable securities totaled USD 117.98 million at year-end, and Kalaris said this is expected to fund operations into the fourth quarter of 2027. On the pipeline, Kalaris reported positive initial Phase 1a single-ascending-dose data for TH103 in treatment-nave nAMD patients, said preliminary Phase 1b/2 data are expected in the first half of 2027, and plans to initiate Phase 3 trials by year-end 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7SVnXg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","BK4585","BK4588","IE00BN0W2V16.EUR","KLRS","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","NDAQ","LU2095319765.USD","IE00BN0W2W23.USD","BK4139","BK4112","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620212494","title":"Press Release: Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620212494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620212494?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:00","pubTimestamp":1773748800,"startTime":"0","endTime":"0","summary":"Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027. Intend to initiate Phase 3 clinical trials by year-end 2027. Completed oversubscribed $50.0 million private placement in December 2025. $118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones. \"This past year was truly transformational for Kalaris,\" said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics. \"Following our initial listing as a public company in March 2025, we continued to advance our clinical program for TH103 throughout the year, culminating with the disclosure of positive initial Phase 1a single ascending dose data and concurrent oversubscribed private placement. In Q3 2025, we began to enroll patients in our Phase 1b/2 multiple ascending dose trial which is desi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","CST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":51,"code":"91000000","status":"200"}]}}